Here is the design of a clinical trial:

Official Title: Fostering Resilience to Psychosocial and HIV Risk in Indian MSM

Included conditions:
- HIV Infection
- Sexual Behavior
- Health Behavior

Study Armgroups:
- {'label': 'Self-acceptance behavioral intervention', 'type': 'EXPERIMENTAL', 'description': 'The intervention will consist of individual and 4 group counseling sessions and 6 individual counseling sessions. The individual sessions are focused on specific individualized risk reduction plans, whereas the group sessions are focused on increasing self-acceptance and reducing HIV risk. Additionally, participants in this arm will receive HIV and STI counseling and testing.', 'interventionNames': ['Behavioral: Self-acceptance based intervention', 'Behavioral: HIV/STI counseling and testing']}
- {'label': 'Comparison/Control', 'type': 'OTHER', 'description': 'The comparison group will receive HIV and STI counseling and testing.', 'interventionNames': ['Behavioral: HIV/STI counseling and testing']}

Interventions:
- {'type': 'BEHAVIORAL', 'name': 'Self-acceptance based intervention', 'description': 'The intervention will consist of HIV/STI counseling and testing as well as individual counseling sessions and group sessions. The primary focus of the group sessions are to help foster self-acceptance by the support from the group, as well as learn skills to reduce distress and HIV risk. The primary purpose of the individual sessions is to help develop and implement an individualized plan for HIV risk reduction, and, as needed and available, linkage to other services.', 'armGroupLabels': ['Self-acceptance behavioral intervention']}
- {'type': 'BEHAVIORAL', 'name': 'HIV/STI counseling and testing', 'description': 'The counseling component is standard of care in India and will focus on HIV/STI risk and how to minimize risk. This is followed by biological testing for HIV and STIs.', 'armGroupLabels': ['Comparison/Control', 'Self-acceptance behavioral intervention']}

Primary Outcomes:
- {'measure': 'Changes in frequency of condomless sex', 'description': 'Self-reported insertive or receptive anal sex without the use of a condom.', 'timeFrame': '4 month visit, 8 month visit, 12, month visit'}
- {'measure': 'Number of incident STIs from Baseline', 'description': 'Chlamydia, gonorrhea, syphilis, and HIV', 'timeFrame': '12 month visit'}

Please estimate the sample size based on the assumption: 
Alpha level of 0.05, power of 90%, and an attrition rate of 20% between baseline assessment and 12-month follow-up.
Power considerations and sample size calculations
          The power analysis for the primary aim is based on detecting a 30% (or greater) difference in 12-month STI incidence and sexual risk (number of unprotected anal sex acts in the past 4Â months, baseline to 12-month follow-up) between the intervention and control. Based on this data, with an alpha level of 0.05 and a power of 90%, 480 study completers are needed. Assuming an attrition rate of 20% between the baseline assessment and 12-month follow-up, we need 600 study completers. However, in an attempt to have approximately 8 participants in each batch, our goal is to randomize 608 participants.